Company Overview and News

84
How US tax reform rewards companies that shift profit to tax havens

4h channelnewsasia
The corporate tax cut passed by U.S. President Donald Trump and fellow Republicans that was in part designed to help dissuade U.S. companies from moving profits overseas may instead make the practice a lot more rewarding.
PFZ BSX MSFT 500680 PFE PFIZER SNPS

84
How U.S. tax reform rewards companies that shift profit to tax havens

4h reuters
(Reuters) - The corporate tax cut passed by U.S. President Donald Trump and fellow Republicans that was in part designed to help dissuade U.S. companies from moving profits overseas may instead make the practice a lot more rewarding.
PFZ BSX MSFT 500680 PFE PFIZER SNPS

180
Can Sprout Pharma’s Latest Revival Really Boost VRX Stock?

2018-06-15 investorplace
At the height of its success, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) thought it could buy drug companies in the billion-dollar range, raise prices and profit. That includes the time the company bought Sprout back in 2015. That gave it access to Addyi, a female libido drug. We all know how that story unfolded. Now, Sprout Pharmaceuticals will make a second attempt to sell the drug but using a different method.
PFZ VRX 500680 PFE PFIZER

16
Alembic Pharma gains 7% on EIR from USFDA for formulation facility at Panelav

2018-06-15 moneycontrol
Alembic Pharmaceuticals share price rallied as much as 6.6 percent in morning trade on Friday after the company received clearance report for its Panelav facility in Gujarat.
PFZ APLLTD 533573 500680 PFE PFIZER

83
Zomedica Announces Changes to Commercialization Leadership Team

2018-06-14 globenewswire
ANN ARBOR, Mich., June 14, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic and pharmaceutical company, today announced the appointment of Michael Schilk as Vice President of Sales and David Eaton as Vice President of Marketing.
ABT PFZ ZOMHF IDXX ZOM 500680 ABT PFE PFIZER

16
Alembic Pharmaceuticals surges 8% on USFDA nod

2018-06-14 moneycontrol
Share price of Alembic Pharmaceuticals added 8 percent intraday Thursday as comapny received approval from the USFDA for its abbreviated new drug application (ANDA) for Doxycycline Hyclate capsules USP, 50 mg and 100 mg.
PFZ APLLTD 533573 500680 PFE PFIZER

16
GSK’s Duo-Combo HIV Treatment Gives Positive Trial Results

2018-06-14 biospace
ViiV Healthcare, established in November 2009 by GlaxoSmithKline, Pfizer Inc. and Shiongi, reported positive results from its Phase III GEMINI-1 and -2 clinical trials for its two-drug regimen for HIV.
PFZ 500680 PFE PFIZER

222
Major Pharmaceuticals Scare Off Short Sellers

2018-06-12 247wallst
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
PFZ TEVJF MRK TEVA TEVVF ABBV LLY 500680 PFE PFIZER ABBV BMY

129
Novavax: Status, Competition, Buyout Prospects

2018-06-08 seekingalpha
Even if Novavax successfully meets its development challenges, it will likely face significant competitive pressures as it works to commercialize its products.
PFZ NVO 500680 NVAX PFE PFIZER SNY

17
PRESS DIGEST- British Business - June 8

2018-06-08 reuters
June 8 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
PFZ LNSTY 500680 PFE PFIZER

243
8 Bitcoin Stocks That You Won’t Lose Your Shirt Over

2018-06-07 investorplace
Bitcoin (BTC-USD, BCH-USD) may not have the trust of Wall Street institutions just yet, but millennials are all in. Blockchain Capital recently conducted a study of 2,000 millennials (aged 18-34) and asked them to make a theoretical choice between owning $1,000 in bonds or stocks and $1,000 in bitcoin: Thirty percent chose bitcoin.
IBM OSTK PFZ SQ SQNXF SAPGF PFIZER SAP RY AMZN JPM TWTR ACN MSFT 500680 PFE

16
Pfizer wins appeal against UK fine for epilepsy drug price hike

2018-06-07 reuters
LONDON, June 7 (Reuters) - Pfizer Inc and Flynn Pharma won an appeal on Thursday against fines totalling nearly 90 million pounds ($120 million) imposed in 2016 for ramping up the cost of an epilepsy drug.
PFZ 500680 PFE PFIZER

87
Icahn buys small stake in drugmaker Allergan: sources

2018-06-06 channelnewsasia
Billionaire investor Carl Icahn has acquired a small stake in Allergan Plc at a time when the drugmaker is under pressure from other activist shareholders, people familiar with the matter said on Wednesday.
TBRA PFZ ZLTQ AGN AGN.PRA FRX ACT 500680 PFE PFIZER

87
Icahn buys small stake in drugmaker Allergan: sources

2018-06-06 reuters
(Reuters) - Billionaire investor Carl Icahn has acquired a small stake in Allergan Plc (AGN.N) at a time when the drugmaker is under pressure from other activist shareholders, people familiar with the matter said on Wednesday.
TBRA PFZ ZLTQ AGN AGN.PRA FRX ACT 500680 PFE PFIZER

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

10h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...